Background. Local delivery of antifungals may allow for high concentrations of therapeutic directly in wound beds infected with invasive fungi. In this work, microparticles (MPs) fabricated from a novel biodegradable polymer synthesized from 1,10-decanediol (DD) and fumaric acid were leveraged for the local delivery of voriconazole (VRC) in a murine model of cutaneous aspergillosis. In addition to controlled local delivery of VRC, the MPs also degrade into byproducts which themselves have bioactivity against fungal viability and promote host wound healing.
Methods. The in vitro release kinetics of VRC-loaded MPs were measured over 6 days in PBS at 37 o C under mild agitation. Immunocompromised BALB/c mice with 5 mm full thickness cutaneous defects infected with A. fumigatus were treated with: Group 1) no infection, no treatment; Group 2) no treatment; Group 3) unloaded blank MPs; and Group 4) VRC-loaded MPs (n = 10 per group). Six days after treatment (nine days after initial infection), mice were euthanized. Wound bed size, fungal wound bed CFU, and histological presence of fungi were evaluated to determine the effects of MPs on wound healing and infection.
Results. MPs were capable of releasing VRC at concentrations above A. fumigatus MIC for at least six days. Mice treated with VRC-loaded MPs had significantly decreased wound size than mice with no treatment (64.2% vs. 19.4% wound reduction, P = 0.002) and were not significantly different than uninfected controls (64.2% vs. 58.1%, P = 0.497). Although wound healing was increased with VRC-loaded MPs, total fungal burden was not significantly different between infected groups.
Conclusion. Diol-based MPs are capable of local delivery of VRC to treat infected wound beds in an immunocompromised murine model of cutaneous aspergillosis. VRC-loaded MPs restored normal wound healing. As fungal burden was unchanged, the exact mechanism of enhanced wound healing needs to be further explored.
Disclosures Background. Omadacycline is a novel aminomethylcycline antibiotic in development for acute bacterial skin and skin structure infection (ABSSSI) and community acquired bacterial pneumonia (CABP). The goal of the study was to determine the PK/ PD targets in the murine thigh infection model against a diverse group of SA pathogens including MRSA.
Methods. 10 SA strains (4 MSSA, 6 MRSA) were utilized. MICs were determined using CLSI methods. Single dose murine plasma PK was previously determined in our lab and used for PK/PD analyses. The neutropenic murine thigh infection model was utilized for all treatment studies and drug dosing was by subcutaneous route. Four-fold increasing doses of omadacycline (0.25-64 mg/kg) were administered q12h to groups of mice infected with each strain. Treatment outcome was measured by determining organism burden in the thighs (CFU) at the end of each experiment (24 hours). The Emax Hill equation was used to model the dose-response data to the PK/PD index AUC/MIC. The magnitude of the PK/PD index AUC/MIC associated with net stasis and 1-log kill were determined in the thigh model for all strains.
Results. MICs ranged from 0.25-0.5 mg/L. At the start of therapy, mice had 7.1 ± 0.3 log 10 CFU/thigh. In control mice, the organism burden increased 2.3 ± 0.3 log 10 CFU/thigh over 24 hours. There was a relatively steep dose-response relationship observed with escalating doses of omadacycline. Maximal organism reductions were 4-5 log 10 CFU/thigh compared with untreated controls. Stasis and 1 log-kill (from start of therapy) was observed against each strain. The AUC/MIC magnitude associated with stasis and 1-log kill endpoints are shown in the Conclusion. Omadacycline demonstrated in vivo potency against a diverse group of SA pathogens including MRSA strains. Stasis 24 hours AUC/MIC targets were approximately 24. This is very similar to previous studies of omadacycline against S. pneumoniae (stasis AUC/MIC 18) and other PK/PD evaluations of tetracycline-class antibiotics. 1-log kill targets were only 2-3 fold more than stasis targets for each strain. This data should provide useful in the dose-regimen optimization of omadacycline.
Disclosures Background. Delafloxacin (DLX) is a broad-spectrum fluoroquinolone antibiotic under FDA review for the treatment of ABSSSI. Previous studies determined DLX bacterial stasis and 1-log 10 bacterial reduction free AUC 0-24 / MIC (fAUC 0-24 /MIC) targets for Escherichia coli (EC) and Pseudomonas aeruginosa (PA) in a mouse thigh infection model. The resulting PK/PD targets were used to predict DLX target attainment probabilities (TAP) in humans.
Methods. Monte Carlo simulations were used to estimate TAP with DLX 300 mg IV, q12hr. Human DLX plasma pharmacokinetics were determined in patients with ABSSSI in a Phase 3 clinical trial. Individual AUC values were analyzed and determined to be log-normally distributed. The parameters of the AUC distribution were used to simulate random values for fAUC 24 , which then were combined with random MIC values based on 2014-2015 US distributions of skin and soft tissue isolates of EC (n = 108) and PA (n = 40), to calculate PK/PD TAPs.
Results. DLX fAUC 0-24 /MIC targets for bacterial stasis and 1-log 10 bacterial reduction for EC were 14.5 and 26.2, and for PA were 3.81 and 5.02, respectively. The Monte Carlo simulations for EC predicted TAPs of 98.7% for stasis at an MIC of 0.25 μg/mL, and 99.3% for 1-log 10 bacterial reduction at an MIC of 0.12 μg/mL. The simulations for PA predicted TAPs of 97.3% for stasis and 86.5% for 1-log 10 bacterial reduction at an MIC of 1 μg/mL. 
